Ascend Capital’s Travere Therapeutics TVTX Stock Holding History

Ascend Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-260,728	Closed	-$5.83M	–	234
2018 Q1	$5.83M	Buy	+260,728	New	+$6.21M	0.24%	115
2015 Q1	–	Sell	-31,850	Closed	-$391K	–	213
2014 Q4	$391K	Sell	31,850 -253,150	-89%	-$2.62M	0.02%	154
2014 Q3	$2.57M	Sell	285,000 -22,293	-7%	-$262K	0.08%	160
2014 Q2	$3.61M	Buy	307,293 +42,492	+16%	+$576K	0.12%	145
2014 Q1	$5.61M	Buy	+264,801	New	+$4.07M	0.15%	140

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ascend Capital's TVTX Position: Q2 2018 in Review

Ascend Capital sold out of Travere Therapeutics (TVTX) in Q2 2018, closing a stake of 260,728 shares — an estimated $5.83M sold.

Ascend Capital first reported a position in TVTX in Q1 2014 and held it in 5 quarters. The position peaked at $5.83M in Q1 2018. 129 funds tracked by Wall St. Rank hold TVTX as of Q2 2018.

Ascend Capital reported no remaining Travere Therapeutics position as of Q2 2018 after selling out during the quarter.
Ascend Capital sold 260,728 Travere Therapeutics shares in Q2 2018, an estimated $5.83M.
Ascend Capital first reported a position in Travere Therapeutics in Q1 2014 and held it in 5 quarters.
Ascend Capital's Travere Therapeutics position peaked at $5.83M in Q1 2018.
129 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.